Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 2/20 | 0.48 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364295 | 0.95 | BDKRB2 (0.48) | BDKRB2BDKRB1NTSR1F2RF2 | |
| SCHEMBL29457591 | 0.89 | F2R (0.48) | BDKRB2NTSR1F2RF2NMUR2 | |
| SCHEMBL7935083 | 0.88 | RAMP3 (0.46) | NMUR2 | |
| SCHEMBL10421719 | 0.88 | RAMP3 (0.46) | NMUR2 | |
| SCHEMBL30321462 | 0.86 | F2R (0.48) | BDKRB2NTSR1F2RF2NMUR2 | |
| SCHEMBL29367074 | 0.85 | BDKRB2 (0.50) | BDKRB2NTSR1F2NMUR2 | |
| SCHEMBL29377971 | 0.85 | F2 (0.55) | BDKRB2NTSR1F2APLNR | |
| SCHEMBL28923852 | 0.85 | BDKRB2 (0.50) | BDKRB2NTSR1F2NMUR2 | |
| SCHEMBL29364214 | 0.84 | KEAP1 (0.46) | NTSR1F2 | |
| SCHEMBL29462901 | 0.84 | KEAP1 (0.46) | NTSR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| US-20240342240-A1 | ANTI-ANGIOGENIC TREATMENT USING ECHISTATIN WITH A BLOCKING PEPTIDE | CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) | 2024-10-17 | — | — | US | disclosed |
| EP-3777877-B1 | ADMINISTRATION OF AN ANTAGONIST OF ALPHA 5 BETA1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12053504-B2 | Anti-angiogenic treatment using VLO4 with a blocking peptide | CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240051997-A1 | SAP AND PEPTIDOMIMETIC COMPOSITIONS FOR REDUCING SYMPTOMS OF INFLAMMATION | VIVEX BIOLOGICS GROUP, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20230348534-A1 | SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE | VIVEX BIOLOGICS GROUP, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023191209-A1 | MICELLE INCLUDING HYDROPHILIC PEPTIDE AND USE THEREOF | 주식회사 퓨전바이오텍 | 2023-10-05 | — | — | WO | disclosed |
| EP-4241285-A1 | SYSTEMS AND METHODS FOR EVALUATING GESTATIONAL PROGRESS AND APPLICATIONS THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3768296-B1 | SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE | ARCH BIOSURGERY INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | disclosed |
| US-20220226431-A1 | ANTI-ANGIOGENIC TREATMENT USING VLO4 WITH A BLOCKING PEPTIDE | CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2022099319-A1 | SYSTEMS AND METHODS FOR EVALUATING GESTATIONAL PROGRESS AND APPLICATIONS THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYAN (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11318184-B2 | Anti-angiogenic treatment with a combination of antagonists | CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053504-B2 | Anti-angiogenic treatment using VLO4 with a blocking peptide | VCAM1, ITGB2, ITGA2 | BDKRB2 222/4885BDKRB1 282/4885NTSR1 879/4885 |
| US-20220226431-A1 | ANTI-ANGIOGENIC TREATMENT USING VLO4 WITH A BLOCKING PEPTIDE | VCAM1, ITGB2, ITGA2 | BDKRB2 222/4885BDKRB1 282/4885NTSR1 879/4885 |
| US-20240342240-A1 | ANTI-ANGIOGENIC TREATMENT USING ECHISTATIN WITH A BLOCKING PEPTIDE | VCAM1, KDR, TEK | BDKRB2 132/4885BDKRB1 200/4885NTSR1 456/4885 |
| US-11318184-B2 | Anti-angiogenic treatment with a combination of antagonists | VCAM1, ITGA2, ITGB2 | BDKRB2 229/4885BDKRB1 257/4885NTSR1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.